KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Cost of Revenue data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 2.87% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $19.6 million, up 5.22%, while the annual FY2025 figure was $19.6 million, 5.22% up from the prior year.
  • Cost of Revenue reached $6.0 million in Q4 2025 per RIGL's latest filing, up from $4.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.0 million in Q3 2024 and bottomed at $121000.0 in Q1 2022.
  • Average Cost of Revenue over 5 years is $2.4 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: plummeted 61.71% in 2022, then surged 1008.19% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $487000.0 in 2021, then fell by 29.77% to $342000.0 in 2022, then soared by 1008.19% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then increased by 2.87% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $6.0 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.